| Code | Description | Claims | Beneficiaries | Total Paid |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
42,247 |
33,606 |
$2.90M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
36,456 |
29,835 |
$799K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
18,176 |
17,803 |
$435K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
12,270 |
11,983 |
$401K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
12,241 |
11,980 |
$400K |
| 84443 |
Thyroid stimulating hormone (TSH) |
26,339 |
25,761 |
$359K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
12,042 |
11,890 |
$277K |
| 88142 |
|
11,002 |
10,914 |
$219K |
| 80061 |
Lipid panel |
19,656 |
19,299 |
$215K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
31,234 |
28,644 |
$214K |
| 86803 |
|
12,812 |
12,682 |
$172K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
4,819 |
4,780 |
$151K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
3,807 |
3,204 |
$150K |
| 87506 |
|
623 |
615 |
$144K |
| 36415 |
Collection of venous blood by venipuncture |
39,995 |
34,038 |
$140K |
| 80053 |
Comprehensive metabolic panel |
17,106 |
16,008 |
$140K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
16,565 |
16,299 |
$139K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
18,652 |
17,565 |
$128K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,754 |
18,977 |
$123K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,383 |
2,217 |
$116K |
| 83970 |
|
3,019 |
2,953 |
$111K |
| 86780 |
|
7,384 |
7,263 |
$91K |
| 82607 |
|
6,295 |
6,183 |
$84K |
| 82728 |
|
5,914 |
5,799 |
$73K |
| 87070 |
|
9,840 |
9,470 |
$73K |
| 85610 |
|
11,316 |
5,617 |
$49K |
| 80050 |
General health panel |
974 |
970 |
$46K |
| 87186 |
|
5,721 |
5,428 |
$44K |
| G0471 |
Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) |
9,346 |
5,148 |
$42K |
| 87340 |
|
4,136 |
4,082 |
$40K |
| 0352U |
|
282 |
279 |
$39K |
| 84153 |
|
2,225 |
2,207 |
$38K |
| 83550 |
|
5,494 |
5,384 |
$38K |
| 83735 |
|
6,949 |
6,187 |
$37K |
| 83540 |
|
6,121 |
5,985 |
$35K |
| 84439 |
|
4,355 |
4,268 |
$35K |
| 82670 |
|
1,179 |
1,159 |
$31K |
| 84702 |
|
2,067 |
1,689 |
$31K |
| 86140 |
|
6,625 |
6,220 |
$30K |
| 82570 |
|
6,698 |
6,127 |
$30K |
| 84481 |
|
1,752 |
1,727 |
$27K |
| 80306 |
|
1,748 |
1,690 |
$26K |
| 87077 |
|
3,109 |
2,954 |
$26K |
| 88342 |
|
341 |
317 |
$25K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
916 |
834 |
$25K |
| 86762 |
|
1,707 |
1,690 |
$24K |
| 83001 |
|
1,233 |
1,219 |
$22K |
| 86003 |
|
1,768 |
266 |
$21K |
| 82043 |
|
3,846 |
3,807 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,246 |
1,212 |
$20K |
| 87480 |
|
1,045 |
1,026 |
$20K |
| 87660 |
|
1,045 |
1,026 |
$20K |
| 87510 |
|
1,042 |
1,023 |
$19K |
| 84146 |
|
1,086 |
1,073 |
$19K |
| 82746 |
|
1,447 |
1,429 |
$19K |
| 87493 |
|
594 |
580 |
$19K |
| 85027 |
|
3,033 |
2,766 |
$17K |
| 86706 |
|
1,551 |
1,538 |
$16K |
| 81001 |
|
6,367 |
5,949 |
$16K |
| 82248 |
|
3,411 |
3,016 |
$16K |
| 84403 |
|
651 |
641 |
$15K |
| 80076 |
|
2,119 |
1,986 |
$14K |
| 84144 |
|
659 |
636 |
$13K |
| 86850 |
|
1,436 |
1,414 |
$13K |
| 86769 |
|
319 |
311 |
$12K |
| 86038 |
|
1,053 |
1,029 |
$12K |
| 83880 |
|
302 |
288 |
$12K |
| 83655 |
|
1,036 |
1,027 |
$12K |
| 87209 |
|
648 |
623 |
$11K |
| 84100 |
|
3,040 |
2,704 |
$11K |
| 82947 |
|
2,920 |
2,874 |
$11K |
| 87625 |
|
275 |
274 |
$10K |
| 83516 |
|
673 |
329 |
$10K |
| 80074 |
|
209 |
208 |
$10K |
| 82565 |
|
2,687 |
2,430 |
$10K |
| 85018 |
|
4,695 |
4,374 |
$9K |
| 83002 |
|
528 |
519 |
$9K |
| 88304 |
|
298 |
293 |
$9K |
| 87205 |
|
2,190 |
2,028 |
$8K |
| 86200 |
|
671 |
657 |
$8K |
| 84460 |
|
1,469 |
1,435 |
$7K |
| 87420 |
|
479 |
473 |
$7K |
| 87150 |
|
227 |
221 |
$6K |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
1,018 |
998 |
$6K |
| 87177 |
|
648 |
623 |
$6K |
| 86787 |
|
421 |
415 |
$5K |
| 82784 |
|
541 |
470 |
$5K |
| 83690 |
|
798 |
789 |
$5K |
| 86431 |
|
991 |
984 |
$5K |
| 80164 |
|
583 |
566 |
$5K |
| 84156 |
|
1,508 |
1,432 |
$5K |
| 81003 |
|
2,464 |
2,379 |
$5K |
| 87329 |
|
386 |
383 |
$5K |
| 85007 |
|
1,301 |
1,115 |
$4K |
| 85652 |
|
1,761 |
1,686 |
$4K |
| 84450 |
|
895 |
873 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
98 |
94 |
$4K |
| 84132 |
|
936 |
874 |
$4K |
| 83721 |
|
379 |
371 |
$3K |
| 82533 |
|
227 |
213 |
$3K |
| 86900 |
|
1,102 |
1,089 |
$3K |
| 86901 |
|
1,097 |
1,084 |
$3K |
| 82785 |
|
191 |
187 |
$3K |
| 82550 |
|
463 |
425 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
46 |
38 |
$2K |
| 84550 |
|
568 |
556 |
$2K |
| 86141 |
|
175 |
168 |
$2K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
273 |
271 |
$2K |
| 80069 |
|
289 |
260 |
$2K |
| 86480 |
|
40 |
40 |
$2K |
| 87075 |
|
227 |
213 |
$2K |
| 86376 |
|
140 |
139 |
$2K |
| 86705 |
|
162 |
161 |
$2K |
| 84402 |
|
83 |
80 |
$2K |
| 88341 |
|
16 |
13 |
$2K |
| 82310 |
|
414 |
377 |
$1K |
| 87338 |
|
91 |
91 |
$1K |
| 85379 |
|
133 |
132 |
$1K |
| 84484 |
|
104 |
100 |
$1K |
| 80051 |
|
296 |
264 |
$1K |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
167 |
162 |
$997.33 |
| 81015 |
|
279 |
263 |
$789.37 |
| 81025 |
|
85 |
84 |
$703.24 |
| 86618 |
|
34 |
34 |
$629.19 |
| 82150 |
|
107 |
106 |
$597.88 |
| 86592 |
|
162 |
154 |
$525.10 |
| 87102 |
|
67 |
67 |
$519.75 |
| 86364 |
|
34 |
27 |
$500.91 |
| 80178 |
|
100 |
97 |
$471.80 |
| 88302 |
|
13 |
12 |
$422.10 |
| 82040 |
|
93 |
93 |
$414.43 |
| 85049 |
|
54 |
54 |
$227.44 |
| 83630 |
|
12 |
12 |
$203.00 |
| 87430 |
|
58 |
57 |
$183.82 |
| 84165 |
|
15 |
15 |
$178.26 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,233 |
765 |
$161.59 |
| 87210 |
|
27 |
25 |
$158.79 |
| 82140 |
|
16 |
12 |
$147.94 |
| 82950 |
|
28 |
27 |
$136.78 |
| 85048 |
|
59 |
56 |
$128.88 |
| 85730 |
|
24 |
24 |
$117.67 |
| 82247 |
|
29 |
25 |
$116.94 |
| 84520 |
|
98 |
88 |
$116.76 |
| 83930 |
|
14 |
14 |
$112.36 |
| 82465 |
|
44 |
43 |
$110.75 |
| 83718 |
|
30 |
30 |
$108.42 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
17 |
16 |
$0.00 |
| 86677 |
|
43 |
43 |
$0.00 |